Perioperative changes of procalcitonin levels in patients undergoing liver transplantation

Transplant Infectious Disease

Volumn 16, Issue 5, 2014, Pages 790-796

  Kaido, T ^a   Ogawa, K ^a   Fujimoto, Y ^a   Mori, A ^a   Hatano, E ^a   Okajima, H ^a   Uemoto, S ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Bacteremia; Liver transplantation; Procalcitonin

Indexed keywords

PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTEREMIA; CYTOMEGALOVIRUS INFECTION; DIAGNOSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADVERSE EFFECTS; AGED; BLOOD; CELLULAR IMMUNITY; GRAFT REJECTION; IMMUNOLOGY; LIVER DISEASES; MIDDLE AGED; TIME; YOUNG ADULT;

ADULT; AGED; BACTEREMIA; BIOLOGICAL MARKERS; CALCITONIN; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; LIVER DISEASES; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PERIOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; TIME FACTORS; YOUNG ADULT;

EID: 84907932692     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12282     Document Type: Article

References (23)

1. Kaido T, Egawa H, Tsuji H, et al. In-hospital mortality in adult recipients of living donor liver transplantation: experience of 576 consecutive cases at a single center. Liver Transpl 2009; 15 (11): 1420-1425.
2. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341 (8844): 515-518.
3. Meisner M, Tschaikowsky K, Schnabel S, Schmidt J, Katalinic A, Schüttler J. Procalcitonin-influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Clin Chem Clin Biochem 1997; 35 (8): 597-601.
4. Ugarte H, Silva E, Mercan D, et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999; 27 (3): 498-504.
5. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164 (3): 396-402.
6. Aikawa N, Fujishima S, Endo S, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005; 11 (3): 152-159.
7. Inomata Y, Uemoto S, Asonuma K, et al. Right lobe graft in living donor liver transplantation. Transplantation 2000; 69 (2): 258-264.
8. Ito T, Kiuchi T, Egawa H, et al. Surgery-related morbidity in living donors of right-lobe liver graft: lessons from the first 200 cases. Transplantation 2003; 76 (1): 158-163.
9. Morioka D, Egawa H, Kasahara M, et al. Outcomes of adult-to-adult living donor liver transplantation: a single institution's experience with 335 consecutive cases. Ann Surg 2007; 245 (2): 315-325.
10. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK 506 in pediatric living related liver transplantation. Transplantation 1996; 61 (2): 247-252.
11. Egawa H, Ohdan H, Haga H, et al. Current status of liver transplantation across ABO blood-type barrier. J Hepatobiliary Pancreat Surg 2008; 15 (2): 131-138.
12. Kaido T, Ogura Y, Hata K, et al. Effects of posttransplant enteral nutrition with an immunomodulating diet containing hydrolyzed whey peptide after liver transplantation. World J Surg 2012; 36 (7): 1666-1671.
13. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25 (3): 658-663.
14. Saner F, Olde Damink S, Pavlakovic G, et al. Pulmonary and blood stream infections in adult living donor and cadaveric liver transplant patients. Transplantation 2008; 85 (11): 1564-1568.
15. Brunkhorst FM, Wegscheider K, Forycki ZF, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000; 26 (Suppl 2): S148-S152.
16. van den Broek MA, Olde Damink SW, Winkens B, et al. Procalcitonin as a prognostic marker for infectious complications in liver transplant recipients in an intensive care unit. Liver Transpl 2010; 16 (3): 402-410.
17. Kuse ER, Langefeld I, Jaeger K, et al. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 2000; 28 (2): 555-559.
18. Kunz D, Pross M, Konig W, et al. Diagnostic relevance of procalcitonin, IL-6 and cellular immune status in the early phase after liver transplantation. Transplant Proc 1998; 30 (5): 2398-2399.
19. Fazakas J, Gondos T, Varga M, et al. Analysis of systemic and regional procalcitonin serum levels during liver transplantation. Transpl Int 2003; 16 (7): 465-470.
20. Perrakis A, Yedibela S, Schellerer V, et al. Procalcitonin in the setting of complicated postoperative course after liver transplantation. Transplant Proc 2010; 42 (10): 4187-4190.
21. Kim S, Kim Y, Jun Y, et al. Epidemiology and risk factors for bacteremia in 144 consecutive living-donor liver transplant recipients. Yonsei Med J 2009; 50 (1): 112-121.
22. Kretzschmar M, Kruger A, Schirrmeister W. Hepatic ischemia-reperfusion syndrome after partial liver resection (LR): hepatic venous oxygen saturation, enzyme pattern, reduced and oxidized glutathione, procalcitonin and interleukin-6. Exp Toxic Pathol 2003; 54 (5-6): 423-431.
23. Kornberg A, Grube T, Wagner T, et al. Differentiated therapy with prostaglandin E1 (alprostadil) after orthotopic liver transplantation: the usefulness of procalcitonin (PCT) and hepatic artery resistive index (RI) for the evaluation of early graft function and clinical course. Clin Chem Lab Med 2000; 38 (11): 1177-1180.